Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer

This study is testing a combination of chemotherapy (cisplatin and nab-paclitaxel), immunotherapy (nivolumab), and radiation therapy after surgery for patients with muscle-invasive bladder cancer who want to keep their bladder rather than have it removed entirely. **You may be eligible if...** - You are 18 or older - You have been diagnosed with muscle-invasive bladder cancer (stage T2–T3, no lymph node involvement or spread to other organs) - You had surgery to remove as much of the bladder tumor as possible (TURBT) - You do not have cancer spread to lymph nodes or elsewhere on PET scan **You may NOT be eligible if...** - Your cancer has spread to lymph nodes or other organs - You have small cell bladder cancer histology - You have had prior radiation to the pelvis - You have active autoimmune disease Talk to your doctor to see if this trial is right for you.